Together, these findings have supported amendments to the SIOP PNET5 MB protocol, through incorporation of SHH-TP53 into the SIOP PNET5 MB diagnostic and stratification repertoire, and the inclusion of MYCN-amplified Group 4 tumours with no other high-risk features in the PNET-MB-SR stratum. Here, MYCN is linked to neoplasm.